Effect of angiotensin 2 receptor blockers on chronic obstructive lung disease mortality: A retrospective cohort study

Pulmonary Pharmacology and Therapeutics

Volumn 44, Issue , 2017, Pages 78-82

  Paulin, Pilar ^a   Maritano Furcada, Joaquin ^a   Ungaro, Catalina M ^a   Bendelman, Gisela ^a   Waisman, Gabriel D ^a   Castro, Horacio M ^a   Giunta, Diego H ^a   Ferreyro, Bruno L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONSULTATION; DEATH; DRUG USE; ELECTRONIC HEALTH RECORD; EXPOSURE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; ARGENTINA; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ARGENTINA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85016290592     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2017.03.007     Document Type: Article

References (21)

1. [1] Mannino, D.M., Buist, A.S., Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370 (2007), 765–773.
2. [2] Lopez, A.D., Murray, C.C., The global burden of disease, 1990-2020. Nat. Med. 4 (1998), 1241–1243.
3. [3] Leggett, R.J., Cooke, N.J., Clancy, L., Leitch, A.G., Kirby, B.J., Flenley, D.C., Long-term domiciliary oxygen therapy in cor pulmonale complicating chronic bronchitis and emphysema. Thorax 31 (1976), 414–418.
4. [4] Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E., Connett, J.E., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern Med. 142 (2005), 233–239.
5. [5] Agustí, A., Edwards, L.D., Rennard, S.I., MacNee, W., Tal-Singer, R., Miller, B.E., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One, 7, 2012, e37483.
6. [6] Anthonisen, N.R., Skeans, M.A., Wise, R.A., Manfreda, J., Kanner, R.E., Connett, J.E., et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern Med. 142 (2005), 233–239.
7. [7] Doehner, W., von Haehling, S., Anker, S.D., Lainscak, M., Neurohormonal activation and inflammation in chronic cardiopulmonary disease: a brief systematic review. Wien Klin. Wochenschr 121 (2009), 293–296.
8. [8] Novo, S., Lunetta, M., Evola, S., Novo, G., Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events. Curr. Drug Targets 10 (2009), 20–25.
9. [9] WHOCC. WHOCC - ATC/DDD Index [Internet]. [cited 4 Jan 2016]. Available: http://www.whocc.no/atc_ddd_index/?code=C09CA.
10. [10] Schünemann, H.J., Dorn, J., Grant, B.J., Winkelstein, W. Jr., Trevisan, M., Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the buffalo health study. Chest 118 (2000), 656–664.
11. [11] Bullock, G.R., Steyaert, I., Bilbe, G., Carey, R.M., Kips, J., De Paepe, B., et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol. 115 (2001), 117–124.
12. [12] Marshall, R.P., McAnulty, R.J., Laurent, G.J., Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am. J. Respir. Crit. Care Med. 161 (2000), 1999–2004.
13. [13] Marshall, R.P., Gohlke, P., Chambers, R.C., Howell, D.C., Bottoms, S.E., Unger, T., et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 286 (2004), L156–L164.
14. [14] Mancini, G.B.J., Khalil, N., Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin. Invest Med. 28 (2005), 118–126.
15. [15] Uhal, B.D., Rongqi, W., Jeremy, L., Jiaju, Z., Valerie, S.-C., Gerasimos, F., Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharmacol. Toxicol. 92 (2003), 81–87.
16. [16] Di Marco, F., Marco, G., Marco, V., Pierachille, S., Mario, C., Maria, P., et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm. Pharmacol. Ther. 23 (2010), 159–164.
17. [17] Andreas, S., Herrmann-Lingen, C., Raupach, T., Lüthje, L., Fabricius, J.A., Hruska, N., et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur. Respir. J. 27 (2006), 972–979.
18. [18] Petersen, H., Sood, A., Meek, P.M., Shen, X., Cheng, Y., Belinsky, S.A., et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest 145 (2014), 695–703.
19. [19] Lee, T.A., Bartle, B., Weiss, K.B., Spirometry use in clinical practice following diagnosis of COPD. Chest 129 (2006), 1509–1515.
20. [20] Arne, M., Mats, A., Karin, L., Björn, S., Gunnar, B., Hans, H., et al. How often is diagnosis of COPD confirmed with spirometry?. Respir. Med. 104 (2010), 550–556.
21. [21] Wendling, P., Patrice, W., Spirometry is underused for diagnosis and staging of COPD. Intern. Med. News, 40, 2007, 27.